Verrica Pharmaceuticals Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-06-15: Study NCT07637734; Company role Lead sponsor; Phase Phase 3; Status Recruiting.
- 2026-03-11: Study NCT07457918; Company role Lead sponsor; Phase Phase 3; Status Recruiting.
- 2025-12-17: Study NCT07246590; Company role Lead sponsor; Phase Phase 3; Status Recruiting.
- 2022-02-01: Study NCT05188729; Company role Lead sponsor; Phase Phase 2; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | NCT07637734 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) | Lead sponsor | Phase 3 | Recruiting | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV); Warts | 300 | 2027-07 |
| 2026-03-11 | NCT07457918 Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) | Lead sponsor | Phase 3 | Recruiting | Common Warts (Verruca Vulgaris); Common Warts; Human Papilloma Virus (HPV); Warts | 600 | 2028-05-22 |
| 2025-12-17 | NCT07246590 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | Lead sponsor | Phase 3 | Recruiting | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV); Warts | 300 | 2027-06 |
| 2022-02-01 | NCT05188729 Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma | Lead sponsor | Phase 2 | Completed Results posted | Basal Cell Carcinoma; Skin Cancer; Cancer of the Skin, Basal Cell; Cancer of the Skin; Carcinoma | 92 | 2024-04-15 |
| 2019-06-25 | NCT03981822 A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts | Lead sponsor | Phase 2 | Completed Results posted | Condylomata Acuminata; Papillomavirus Infections; Skin Diseases, Viral; Skin Diseases, Infectious; Skin Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Warts | 105 | 2020-07-08 |
| 2018-03-27 | NCT03487549 Cantharidin and Occlusion in Verruca Epithelium | Lead sponsor | Phase 2 | Completed Results posted | Common Wart; Warts Hand; Warts; Papillomavirus Infections; DNA Virus Infections; Skin Diseases, Viral; Skin Diseases, Infectious; Skin Diseases; Virus Diseases; Tumor Virus Infections; Verruca Vulgaris; Verruca | 56 | 2019-07-15 |
| 2018-03-21 | NCT03377790 Cantharidin Application in Molluscum Patients-1 | Lead sponsor | Phase 3 | Completed Results posted | Molluscum Contagiosum | 266 | 2018-11-26 |
| 2018-02-14 | NCT03377803 Cantharidin Application in Molluscum Patients | Lead sponsor | Phase 3 | Completed Results posted | Molluscum Contagiosum | 262 | 2018-09-26 |
| 2017-06-08 | NCT03186378 Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. | Lead sponsor | Phase 2 | Completed Results posted | Molluscum Contagiosum | 33 | 2018-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |